- Home
- NAAS vs INAB Comparison
NAAS vs INAB Comparison
Compare NAAS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | INAB |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5M | 22.9M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NAAS | INAB |
|---|---|---|
| Price | $2.41 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 3.8K | ★ 39.6K |
| Earning Date | 03-31-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.12 |
| 52 Week High | $4.54 | $4.20 |
Technical Indicators
Market Signals| Indicator | NAAS | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 41.18 |
| Support Level | $2.22 | $1.52 |
| Resistance Level | $3.77 | $2.14 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 72.86 | 4.33 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.